Novavax Inc

NVAXNASDAQUSD
9.49 USD
0.70 (6.87%)AT CLOSE (11:59 AM EDT)
9.39
0.10 (1.10%)
POST MARKET (AS OF 08:00 PM EDT)
Post Market
AS OF 08:00 PM EDT
9.39
0.10 (1.10%)
🔴Market: CLOSED
Open?$9.97
High?$10.13
Low?$9.26
Prev. Close?$10.19
Volume?4.6M
Avg. Volume?5.6M
VWAP?$9.62
Rel. Volume?0.81x
Bid / Ask
Bid?$9.34 × 500
Ask?$9.43 × 300
Spread?$0.09
Midpoint?$9.39
Valuation & Ratios
Market Cap?1.6B
Shares Out?164.4M
Float?154.7M
Float %?94.9%
P/E Ratio?N/A
P/B Ratio?-10.78
EPS?-$0.53
Dividend?0.00%
Ex-Dividend?N/A

NVAX is currently priced at $9.49. Technical and fundamental signals converge bearish — technicals rate "Sell" while fundamentals read "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, exceptional Return on Equity (60.7%) and a bullish Golden Cross on the moving averages. On valuation, NVAX trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
Employees
749
Market Cap
1.6B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
1995-12-05
Address
21 FIRSTFIELD RD
GAITHERSBURG, MD
Phone: 240-268-2000
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)? Neutral(0/3)
Medium-Term (Wave)? Neutral(0/3)
Short-Term (Ripple)? Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
0
Momentum?
2
Short Sent.?
41
Piotroski F-Score?2/9Weak
Altman Z-Score?-4.45Distress
Confidence?66%Moderate
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?29.28%Squeeze Risk
Short Interest?45.3M
Days to Cover?6.4
Free Float154.7M
Avg Daily Volume7.1M
Settlement Date2026-05-15
Financial Health
Current Ratio?2.48Strong
Quick Ratio?2.45Strong
Cash Ratio?0.67Adequate
Debt/Equity?-2.04Low
ValuationATTRACTIVELY VALUEDvs 6 peers + S&P 500
Score
83/100
P/E?
N/A
P/B?
Peers
100
S&P
97
-10.78CHEAP
P/S?
Peers
71
S&P
56
2.62CHEAP
P/FCF?
N/A
EV/EBITDA?
Peers
50
S&P
6
38.7HIGH
EV/Sales?
Peers
86
S&P
64
2.73CHEAP
Returns & Efficiency
ROE?
Peers
100
S&P
93
60.7%STRONG
ROA?
Peers
25
S&P
3
-8.4%WEAK
Cash Flow & Enterprise
FCF?$-97619000
Enterprise Value?$1.6B
Fundamentals ratios updated end of day